Helen Mann
AstraZeneca (Singapore)(SG)
Publications by Year
Research Areas
Lung Cancer Research Studies, Neuroendocrine Tumor Research Advances, Peptidase Inhibition and Analysis, Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer(2016)3,266 cited
- → Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study(2016)636 cited
- → Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer(2023)601 cited
- → Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component(2017)565 cited
- → Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer(2017)526 cited
- Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer(2017)
- → TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer(2020)433 cited
- → Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study(2020)360 cited
- → Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy(2015)298 cited
- → Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN(2022)297 cited